A medical oncologist at a Southwestern AMC speaks about MRD and monitoring usage and trends for melanoma, breast cancer, colorectal cancer, bladder cancer, and lung cancer. Additionally, they speak to implementation of MRD for hepatocellular cancers. This stakeholder is most familiar with Guardant and Natera tests for MRD. They have an optimistic expectation for the adoption of MRD, specifically for CRC applications, and for monitoring in NSCLC and CRC populations, with the caveat that guidelines will be crucial to widespread adoption across the testing paradigm for all cancer types. Speaking to the landscape of competitors, this stakeholder values customer support and EMR integration, and envisions that the future of MRD and monitoring test selection will be dictated by patient’s preferences in addition to the physician’s vendor knowledge.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.